22 Aug 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Wockhardt received final approval from the US FDA for marketing extended-release tablets containing 2.5mg, 5mg and 10mg Felodipine, which are used in treating hypertension and would be launching the product immediately. Felodipine is the generic name for the brand Plendil, marketed in the US by Astra Zeneca.
Dr Habil Khorakiwala, founder chairman and group CEO, Wockhardt, said that, "We have received four ANDA approvals in the last 5 days and two of these are extended release pharmaceutical formulations. This definitely is a reflection of Wockhardt's R&D prowess in indigenously developing such products."
Wockhardt will be manufacturing the Felodipine API in its facility at Ankleshwar, India, and the tablets of Felodipine ER at its facility in Aurangabad, India. The technology for the API and the extended-release tables were developed in-house.